In a context of rapid upheaval, the pharmaceutical industry She faces challenges with her characteristic firmness, adapting quickly and decisively. Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2026) It recognizes the importance of regulatory authorities, government agencies, and institutions that protect patients by ensuring the safety, efficacy, and quality of medicines. Its representatives will highlight the latest standards for clinical trials, manufacturing, and marketing in Amsterdam on April 20 and 21.
Karel van der Waarde, from the Lucerne University of Applied Sciences and Arts, It presents its findings on whether patients and caregivers receive relevant medical information (a study that spans medical engineering, life sciences and data science) in a patient-centered session, in a context where concerns about equity are increasing.
Chakravarthi AVPS, President of the Federation of Pharmaceutical Entrepreneurs, It offers an overview of global strategies to accelerate access to innovative therapies, connecting equity, regulation, and technology. The program also includes perspectives from ISPE, an international non-profit organization that supports pharmaceutical professionals in 120 countries. At PHARMAP 2026, Natalia Vtyurina represents ISPE and analyzes the transition from Pharmacy 4.0 to 5.0 and how a human-centered strategy drives digital transformation.
Congress joins GS1, developer of the leading global standards for the supply chain. Its common language facilitates traceability and strengthens patient safety in the pharmaceutical sector. Sophie Molle, Director of Strategic Alliances for the Health Sector, addresses global standards in the digitization of healthcare.
While PHARMAP 2026 fosters international dialogue, the technical advisor Anne Catherine Diouf It represents the Pharmaceutical Regulatory Agency of Senegal, following Senegal's achievement in December 2024 as the first Francophone African country to obtain WHO ML3 certification for medicine regulation, a key aspect for the Vision 2050 pharmaceutical sovereignty goals.
By ensuring safety while simultaneously driving innovation and access, regulatory institutions rely on harmonization, transparency, and agile science to protect patients without hindering progress. PHARMAP 2026 puts this into practice, uniting pharmaceutical manufacturers, CDMOs, and regulatory bodies to build a safer and more resilient medicines ecosystem. You can discover the full program here. here.
